Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
04 June 2019 | Story Valentino Ndaba | Photo Charl Devenish
Prof Cathryn Tonne
Air pollution not only costs lives, it costs money too. Pictured is Prof Cathryn Tonne presenting a guest lecture on air pollution at the Bloemfontein Campus.
Health effects associated with ambient air pollution (AAP) have been well documented. Subsequently, the relationship between pollution and financial outcomes have also become a focus for case studies globally. An Environmental Research journal article revealed that “low and middle-income countries are disproportionately affected by the global burden of adverse health effects caused by AAP”. 

A high price to pay

In 2012, high concentrations of air pollution caused 7.4% of all deaths, costing South Africa up to 6% of its Gross Domestic Product. According to the recent International Growth Centre study conducted by senior University of Cape Town researchers, this is a direct consequence of the country’s heavy dependence of fossil fuels, a source of health-damaging air pollution and greenhouse pollutants.

Stunted human and economic growth

These South African statistics are attested to by Prof Cathryn Tonne who recently presented a guest lecture on air pollution which was hosted by the University of the Free State (UFS) Business School.

“Air pollution can affect economic development through several pathways, and health is an important one. Air pollution is linked to shorter life expectancy, chronic disease, asthma exacerbation and many other health outcomes that result in absenteeism from work and school. These have large direct costs to the health system.” 

Prof Tonne says that air pollution exposure in children is linked to reduced cognitive development, with important impacts on human capital. As a result, children are not reaching their full potential in terms of neurodevelopment, which has an effect on their income prospects and the economy as a whole. 

Resolving a looming disaster

Technology may be employed to radically clean the air. Cities need to lead in the reduction of air pollution by promoting renewable energy, using active transport such as walking or cycling, and investing in infrastructure to make this safe and attractive. 

With researchers playing a major role in strengthening the case for aggressive air pollution control, the government needs to implement policies in order to control sources of air pollution. This global health and economic issue also requires individuals and communities to play their part to improve air quality.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept